Rivaroxaban in high-risk patients
Authors:
Jindřich Špinar 1; Lenka Špinarová 2
Authors place of work:
Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice
1; I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
2
Published in the journal:
Vnitř Lék 2017; 63(6): 424-430
Category:
Reviews
Summary
Blockade of factor Xa becomes a routine part of clinical practice instead of vitamin K blockade with warfarin, providing a more beneficial and safer effect. The main indications are prevention of stroke and systemic embolism in adults with nonvalvular atrial fibrillation, deep vein thrombosis and pulmonary embolism. Rivaroxaban has the largest number of data across high risk patients. Rivaroxaban is an oral selective anti Xa inhibitor with well predictive pharmacokinetics and pharmacodynamics. It inhibits thrombin formation for 24 hours, is well absorbed and biological availability is 80–100 %. The excretion is mainly renal and the mean elimination time is 5–9 hours in younger and 11–13 hours in elderly. The pharmacokinetics is minimally influenced by sex and age. The ROCKET AF trial has shown in 14 246 high-risk patients a trend to lowering stroke and systemic embolization by rivaroxaban compared to warfarin without a bleeding increase. The number of events per 100 patient-years was 1.71 in group treated with rivaroxaban compared to 2.16 treated with warfarin (p < 0.001 for non inferiority). A sub-analysis of the ROCKET AF trial has shown numerically trend to higher efficacy and safety of rivaroxaban in patients with moderate renal insufficiency compared to warfarin. Mild hepatic impairment did not significantly affect the pharmacokinetics or pharmacodynamics of rivaroxaban, compared with healthy subjects. The effects by age and concomitant diseases are discussed. The X-VeRT trial shows a new indication for rivaroxaban – electric cardioversion.
Key words:
age – anticoagulation – heart failure – high risk patients – renal insufficiency – thromboembolic disease
Zdroje
1. Špinar J, Vítovec J. Studie ROCKET AF – konec warfarinu na obzoru? Kardiol Rev Int Med 2011; 13(2): 106–108.
2. Špinar J, Vítovec J. Antikoagulační léčba u fibrilace síní. Acta medicinae 2014; 3(9): 18–23.
3. Špinar J, Vítovec J, Špinarová L et al. Rivaroxaban v léčbě fibrilace síní. Farmakoterapie 2013; 9(1): 6–12.
4. Vítovec J, Špinar J. Antikoagulační léčba u srdečního selhání a hypertenze. In: Widimský J, jr. Arteriální hypertenze – současné klinické trendy XIII. In: Triton: Praha 2016: 157–162. ISBN 978–80–7387–883–2.
5. Špinar J, Špinarová L. Nové indikace přímých antikoagulancií v roce 2017. Remedia 2017; 27(2): 132–135.
6. Böttger B, Thate-Waschke IM, Bauersachs R et al. Preferences for anticoagulation therapy in atrial fibrillation: the patients’ view. J Thromb Thrombolysis 2015; 40(4): 406–415. Dostupné z DOI: <http://dx.doi.org/10.1007/s11239–015–1263-x>.
7. Čihák R, Haman L, Táborský M. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: Summary of the document prepared by the Czech Society of Cardiology. Cor et vasa 2016; 58(6): e636-e683. Dostupné z DOI: <https://doi.org/10.1016/j.crvasa.2016.11.005>.
8. Patel MR, Mahaffey KW, Garg J et al. [ROCKET AF Investigators]. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883–891. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1009638>.
9. Kubitza D, Becka M, Mueck W et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2010; 70(5): 703–712. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2125.2010.03753.x>.
10. Fox KAA, Piccini JP, Wojdyla D et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32(19): 2387–2394. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr342>.
11. Hohnloser SH, Connolly SL. Atrial fibrillation, moderate chronic kidney disease, and stroke prevention: new anticoagulants, new hope. Eur Heart J 2011; 32(19): 2347–2349. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr344>.
12. Kubitza D, Roth A, Becka M et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013; 76(1): 89–98. Dostupné z DOI: <http://dx.doi.org/10.1111/bcp.12054>. Erratum in Br J Clin Pharmacol 2013; 76(3): 489.
13. Urbánek K. Farmakologický profil rivaroxabanu. Kardiol Rev Int Med 2017; 19(1): 39–44.
14. Halperin JL, Hankey GJ, Wojdyla DM et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of strokw and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 130(2): 138–146. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005008>.
15. van Diepen S, Hellkamp AS, Patel MR et al. Efficacy and safety of rovaroxaban in patients with heart failure and nonvalvular atrial fibrillation. Insight from ROCKET AF. Circ Heart Failure 2013; 6(4): 740–747. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000212>.
16. Heidbuchel H, Verhamme P, Alings M et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17(10): 1467–1507. Dostupné z DOI: <http://dx.doi.org/10.1093/europace/euv309>.
17. Kirchov P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893–2962. <http://dx.doi.org/10.1093/eurheartj/ehw210>.
18. Mahaffey KW, Stevens SR, White HD et al. Ischaemic cardiac outcomes in patients with atrial wibrillation treated with vitamin K antagonism or factor Xa inhibition: result from ROCKET AF trial. Eur Heart J 2014; 35(4): 233–241. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht428>.
19. Cappato R, Ezekowitz MD, Klein AL et al. [X-VeRT Investigators]. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014; 35(47): 3346–3355. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu367>.
20. Patel MR, Mahaffey KW, Garg J et al. [ROCKET AF Investigators]. Rivaroxaban versus warfarin in nonvalvular atrial fibrillatio. N Engl J Med 2011; 365(10): 883–891. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1009638>.
21. Granger CB, Alexander JH, McMurray JJ et al. [ARISTOTLE Committees and Investigators]. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11): 981–992. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1107039>.
22. Giugliano RP, Ruff CT, Braunwald E et al. [ENGAGE AF-TIMI 48 Investigators]. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093–2104. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1310907>.
23. Connolly SJ, Ezekowitz MD, Yusuf S et al. [RE-LY Steering Committee and Investigators]. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361(12): 1139–1151. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0905561>.
24. Eikelboom JW, Wallentin L, Connolly SJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123(21): 2363–2372. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.004747>.
25. FDA. FDA Briefing Information for the Cardiovascular and Renal Drugs Advisory Committee. Dostupné z WWW: <https://archive-it.org/collections/7993?q=FDA+Briefing+Information+for+the+Cardiovascular+and+Renal+Drugs+Advisory+Committee&show=ArchivedPages&hitsPerDupe=0&go=Search+the+Archive>.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2017 Číslo 6
Najčítanejšie v tomto čísle
- Primary testicular lymphoma
- “Snags” connected with establishing the vitamin D
- Insulin pump in type 2 diabetes: B-cell focused treatment
- Two perspectives on venous thromboembolism in oncology